Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2023, 5(7); doi: 10.25236/IJFM.2023.050703.

Recent Advances of Oncolytic Virus in Esophageal Cancer Therapy


Kun Yang1, Junhai Li2

Corresponding Author:
Junhai Li

1Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, China

2Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, China


Esophageal cancer (EC) is a common digestive tract tumor with high invasiveness and poor prognosis. According to global statistics in 2020, EC ranks 7th in incidence and 6th in mortality. Traditional treatment options include surgery, radiotherapy, and chemotherapy, but often produce adverse reactions, drug resistance, and poor prognosis. In recent years, tumor immunology has rapidly developed, and biological immune therapy has become a new treatment method. Oncolytic viruses (OV) have shown good therapeutic effects in the treatment of EC in recent years. Recombinant adenoviruses OBP-301 (telomelysin) and H101 are widely studied OVs in EC treatment. With the rapid development of tumor immunotherapy, OV therapy has become a research hotspot in the treatment of EC. This review article summarizes the mechanism of action of OVs and their research progress in the treatment of EC.


Esophageal cancer; Immunotherapy; Oncolytic virus; Review

Cite This Paper

Kun Yang, Junhai Li. Recent Advances of Oncolytic Virus in Esophageal Cancer Therapy. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 7: 13-18. https://doi.org/10.25236/IJFM.2023.050703.


[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: a cancer journal for clinicians, 2021, 71(3): 209-49.

[2] Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer communications (London, England), 2021, 41(10): 1037-48.

[3] He Y, Liang D, Du L, et al. Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China[J]. Cancer communications (London, England), 2020, 40(10): 531-44.

[4] Tang C, Li L, Mo T, et al. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical[J]. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, 24(9): 1682-701.

[5] Rosenberg S A. Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment [J]. Nature reviews Clinical oncology, 2014, 11(11): 630-2.

[6] Clemens M J. Targets and mechanisms for the regulation of translation in malignant transformation [J]. Oncogene, 2004, 23(18): 3180-8.

[7] Kaufman H L, Kohlhapp F J, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs[J]. Nature Reviews Drug Discovery, 2015, 14(9): 642-62.

[8] Rahman M M, McFadden G. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy[J]. Cancers, 2021, 13(21).

[9] Bommareddy P K, Kaufman H L. Unleashing the therapeutic potential of oncolytic viruses[J]. The Journal of clinical investigation, 2018, 128(4): 1258-60.

[10] De Graaf J F, De Vor L, Fouchier R A M, et al. Armed oncolytic viruses: A kick-start for anti-tumor immunity [J]. Cytokine & growth factor reviews, 2018, 41: 28-39.

[11] Hutzen B, Bid H K, Houghton P J, et al. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin[J]. BMC cancer, 2014, 14: 206.

[12] Ruffell B, Affara N I, Coussens L M. Differential macrophage programming in the tumor microenvironment [J]. Trends in immunology, 2012, 33(3): 119-26.

[13] Shirakawa Y, Tazawa H, Tanabe S, et al. Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments[J]. European journal of cancer (Oxford, England : 1990), 2021, 153: 98-108.

[14] Lu W, Zheng S, Li X F, et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial[J]. World journal of gastroenterology, 2004, 10(24): 3634-8.

[15] Garber K. China approves world's first oncolytic virus therapy for cancer treatment[J]. Journal of the National Cancer Institute, 2006, 98(5): 298-300.

[16] Li C, Zhu M, Lu Q, et al. Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic efficacy in esophageal cancer[J]. 2023, 11(5): 193.

[17] Jiang Y Q, Zhang Z, Cai H R, et al. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines[J]. International journal of clinical and experimental pathology, 2015, 8(11): 13785-94.

[18] Shiina M, Lacher M D, Christian C, et al. RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses[J]. Cancer Gene Therapy, 2009, 16(11): 810-9.

[19] Goradel N H, Baker A T, Arashkia A, et al. Oncolytic virotherapy: Challenges and solutions[J]. Current problems in cancer, 2021, 45(1): 100639.

[20] Zhang B, Huang J, Tang J, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial[J]. 2021, 9(4): e002224.

[21] Sinkovics J G, Horvath J C. Newcastle disease virus (NDV): brief history of its oncolytic strains[J]. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology, 2000, 16(1): 1-15.

[22] Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects[J]. International journal of oncology, 2001, 18(5): 945-52.

[23] Galanis E, Markovic S N, Suman V J, et al. Phase II trial of intravenous administration of Reolysin(Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma[J]. Molecular therapy: the journal of the American Society of Gene Therapy, 2012, 20(10): 1998-2003.

[24] Zhang Y, Liang M, Sun S, et al. Bortezomib enhances the antitumor effects of the oncolytic adenovirus in renal cell carcinoma treatment[J]. Oncology Reports, 2021, 45(3): 945-52.

[25] Nijman H W, Hoogeboom B N, Heskamp S, et al. First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers[J]. Molecular therapy: the journal of the American Society of Gene Therapy, 2021, 29(2): 652-61.

[26] Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus[J]. Clinical Cancer Research, 2008, 14(1): 259-69.

[27] Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers[J]. Journal for ImmunoTherapy of Cancer, 2016, 4: 17.

[28] Karapanagiotou E M, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2012, 18(7): 2080-9.

[29] Andtbacka R H, Kaufman H L, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33(25): 2780-8.

[30] Shimoyama S. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)[J]. British Journal of Haematology, 1991, 79(3): 428-37.

[31] Samson A, Scott K J, Taggart D, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade[J]. Science translational medicine, 2018, 10(422).

[32] Hara H, Kobayashi A, Yoshida K, et al. Detection of HTLV-I tax-rex and pol mRNA in the spinal cord and lymph node of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients by in situ hybridization[J]. J Neurol Sci, 1992, 109(1): 7-13.

[33] Katsura Y, Sasaki J, Mohri I, et al. Maternal transmission of HTLV-1 other than through breast milk: discrepancy between the polymerase chain reaction positivity of cord blood samples and the subsequent seropositivity of individuals [J]. Journal of Pediatric Hematology/Oncology, 2005, 27(1): 10-3.

[34] Bangham C R, Araujo A, Yamano Y, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis[J]. Nature Reviews Disease Primers, 2015, 1: 15012.

[35] LaGrenade L, Hanchard B, Fletcher V, et al. Infective dermatitis of Jamaican children: a marker for HTLV-I infection[J]. Lancet, 1990, 336(8727): 1345-7.

[36] Higuchi Y, Izumi N, Mohammadzadeh N, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP[J]. Journal of Neuroinflammation, 2020, 17(1): 35.

[37] Azimi N, Jacobson S, Leist T, et al. Involvement of cytokines in human T cell lymphotropic virus type I neuropathogenicity[J]. Journal of Leukocyte Biology, 1999, 66(4): 407-16.